1.15
+4.27%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Pharming Group
Its shares trade on Euronext Amsterdam under the ticker PHARM.AS. It has been listed since 2 July 1998. In the fiscal year to 31 December 2025, it reported revenue of $326.1m and net income of $2.6m. At that date it held total assets of $433.5m and shareholders' equity of $240.3m.
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 2 Jul 1998
- Employees
- 212
- Website
- pharming.com ↗
Leadership
Pay as last reported
- Dr. Richard PetersNon-Executive Independent Chairman of the Board$154,000
- Mr. Fabrice ChouraquiChief Executive Officer, Executive Director, since 2025
- Mr. Kenneth LynardChief Financial Officer
- Mr. Jeroen WakkermanChief Financial Officer
- Mrs. Mireille SandersChief Operations Officer
- Ms. Ines BernalChief People Officer
- Mr. Ruud Van OutersterpChief Ethics and Compliance Officer
- Dr. Alexander BreidenbachChief Business Officer
- Dr. Anurag RelanChief Medical Officer
- Mr. Stephen ToorChief Commercial Officer
- Mr. Steven BaertNon-Executive Independent Director$101,000
- Mr. Leonard KruimerNon-Executive Independent Director$104,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 53
- Environment
- 22
- Social
- 74
- Governance
- 62
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Established track record: Pharming Group NV has a strong history of developing and launching successful pharmaceutical products.
- Innovative research and development: The company invests heavily in R&D, which allows it to stay at the forefront of advanced medical therapies.
- Strong intellectual property portfolio: Pharming Group NV holds numerous patents for its products, providing a competitive advantage in the market.
Weaknesses
- Dependence on limited product portfolio: The company heavily relies on a few key products for its revenue, leaving it vulnerable to market fluctuations.
- Regulatory challenges: The pharmaceutical industry is heavily regulated, and any changes in regulations or delays in obtaining approvals can impact Pharming Group NV's operations.
- High research and development costs: While investment in R&D is a strength, it also presents a financial burden for the company, potentially affecting profitability.
Opportunities
- Market expansion: Pharming Group NV can explore new markets and regions to increase its customer base and revenue streams.
- Collaborations and partnerships: Forming strategic alliances can help the company access new technologies, expertise, and distribution channels.
- Growing demand for rare disease treatments: As the awareness and need for rare disease therapeutics increase, Pharming Group NV can leverage its expertise in this area.
Threats
- Intense competition: The pharmaceutical industry is highly competitive, with established players and new entrants vying for market share.
- Pricing pressures: Pricing pressures from governments, payers, and insurers can impact the profitability of Pharming Group NV's products.
- Intellectual property challenges: The risk of patent infringements or challenges to existing patents can threaten Pharming Group NV's market exclusivity.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.